[The effect of insulin-like growth factor I and insulin on intrauterine fetal growth retardation].

Obstetrics and Gynecology Hospital of Zhejiang Medical University, Hangzhou 310006.
Zhonghua fu chan ke za zhi 04/1999; 34(4):222-4.
Source: PubMed

ABSTRACT To evaluate the role of insulin-like growth factor I (IGF-I) and insulin (Ins) in the occurrence of intrauterine fetal growth retardation (IUGR).
The study group included 17 women with IUGR, and 38 normal third trimester pregnant women were served as control. Maternal venous blood samples were collected from all cases before cesarean section. Umbilical venous blood and amniotic fluid were collected at the time of operation. The concentrations of Ins were measured by radioimmunoassay and concentrations of IGF-I were assayed by ELISA.
The maternal serum IGF-I in IUGR group (117.29 micrograms/L) was significantly lower than that in the control group (207.07 micrograms/L) (P < 0.002). The umbilical serum IGF-I in IUGR group (16.73 micrograms/L) was significantly lower than that in the control (44.89 micrograms/L) (P < 0.001). There was no significant difference of maternal serum Ins between IUGR group (12.18 mIU/L) and control group (7.13 mIU/L).
The change of IGF-I and Ins levels in maternal and umbilical serum may play an important role in the pathophysiological changes in IUGR.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer may originate in utero. We reviewed the available evidence on the association between birthweight and the risk of breast cancer. To date, 26 research papers addressing this issue have been published. The majority of studies identified a positive link between birthweight and premenopausal, but not postmenopausal, breast cancer. The relative risk estimate for breast cancer comparing women with high birthweight to women with low birthweight combining all studies including both pre- and postmenopausal breast cancer was 1.23 (95% confidence interval 1.13-1.34). The mechanisms underlying this association likely include elevated levels of growth factors that may increase the number of susceptible stem cells in the mammary gland or initiate tumors through DNA mutations. Loss of imprinting (LOI) of growth hormone genes relevant for intrauterine growth, such as insulin-like growth factor 2 (IGF2), leads to abnormally high levels of these hormones evidenced by high birthweight. LOI of IGF2 has also been found in mammary tumor tissue. The role of environmental factors that stimulate such epigenetic regulation of gene expression remains to be elucidated.
    International Journal of Cancer 12/2006; 119(9):2007-25. · 6.20 Impact Factor